Clinical Trial Update: A Study to Assess Adverse Events and Change in Disease Activity of HArmonyCa Lidocaine Injectable Gel for Mid Face Soft Tissue Augmentation in Adult Participants [Phase 3]

View source ↗

Summary

This is a completed Phase 3 clinical trial update from Allergan. It evaluates adverse events and changes in disease activity for HArmonyCa Lidocaine Injectable …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mid-face Volume Deficit

Drugs mentioned

• HArmonyCa Lidocaine Injectable Gel (lidocaine injectable gel)

Snippet

Sponsor: Allergan | Conditions: Mid Face Volume Deficit | Phase 3 | Status: COMPLETED